Nora Frey

Nora brings more than 20 years of professional experience in the healthcare research and investment field.

She is currently a Managing Partner at Cederberg GmbH, Switzerland.

She studied modern biology (microbiology, biochemistry) and economics in Basel and holds a master’s degree in Microbiology and a PhD in Biochemistry in the field of drug-induced autoimmune diseases from the University of Basel. She was partner at Bellevue Group, Zug, Switzerland and part of the BB Biotech management team managing up to CHF 4 bn in public and private biotech investments. In 2000, she conceived of, and founded Adamant Biomedical Investments AG in Basel, Switzerland, a successful healthcare asset management boutique, which manages different healthcare funds. As CIO, Nora headed research and portfolio management, and led the innovation and expansion of the range of funds under management. During this time, the funds under management grew from CHF 50 m to approximately CHF 1 bn. In addition, to research and fund management experience, Nora’s roles included advising numerous companies, and collaboration with SWX and ZKB’s Corporate Finance group regarding listings of foreign companies in Switzerland.

Among several other awards, Nora was voted finalist in the Ernst &Young Entrepreneur of the Year Award in Switzerland. During Nora’s time at Adamant, Nora managed the inception of the company and the collaboration with SwissLife, co-managed the Management Buy-Out and later the sale of the company to Zürich Kantonal Bank, ZKB. She was also responsible for the establishment of a subsidiary of Adamant, Adamant Ventures Ltd., in Edinburgh, UK, that focused on venture capital investing. Towards the end of 2008, Nora left Adamant to found Cederberg GmbH.

Nora is a citizen of Germany and Switzerland.